

In Response to Office Action dated December 30, 2003

#### REMARKS

According to the present Office Communication, the communication filed on March 27, 2003 was not fully responsive to the Office Communication mailed February 20, 2003 for the reason(s) set forth on the accompanying Notice to Comply With the Sequence Rules of CRF Diskette Problem Report. Applicant was given one month to correct the deficiency because Applicant's previous reply appeared to be a bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 – 1.825). On February 9, 2003, Sam Borkowsky, agent for Applicant, phoned Mark Spencer (517-272-2510) for assistance. Mr. Spencer described, field-by-field, the changes to the previously submitted sequence listing that would produce an acceptable sequence listing. An amended sequence listing was prepared and a copy of it was sent to Mr. Spencer by FAX on February 9, 2004. On February 10, 2004, during a conversation with Sam Borkowsky, Mr. Spencer stated that the revised sequence listing was acceptable. Applicant respectfully requests that this amended sequence listing, which is being submitted with the 'SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE' that accompanies this amendment, be entered into the present patent application to comply with the 'NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES' that accompanied the present Office Communication. Please note that the Notice to Comply that was sent with the present Office Communication related to a different application. Sam Borkowsky, agent for Applicant, notified Examiner Davis about this and the Examiner subsequently forwarded by FAX a corrected Notice to Comply.

Applicant is also submitting with this amendment an exact copy of the revised 'Sequence Listing' in computer readable form (CRF). In the revised sequence listing, several fields for each of the oligopeptides have been omitted, as compared to the previously submitted sequence listing, and a replacement comment inserted which states that each sequence is a synthesized sequence, which complies with the

SN 09/859,701  
Docket No. S-94,661  
In Response to Office Action dated December 30, 2003

requirements of the rules for a sequence listing. As indicated on page 5, lines 17-20 of the present application as originally filed, the sequences are those of oligopeptides purchased in bead-supported form from the commercial vendor Biopeptide Co.

Applicant respectfully requests that this amendment be entered into the present patent application. All currently pending claims are in condition for allowance, and such action at an early date is earnestly solicited. No new matter has been added by the above changes.

Respectfully submitted,

Date: February 17, 2004

Samuel L. Borkowsky  
Signature of Agent

Reg. No. 42,346  
Phone (505) 665-3111

Samuel L. Borkowsky  
Los Alamos National Laboratory  
LC/IP, MS A187  
Los Alamos, New Mexico 87545